Clinical trials demonstrated decreasing rates of bronchopulmonary dysplasia in preterm infants with hypoxic respiratory failure treated with inhaled nitric oxide (iNO). However, the molecular and biochemical effects of iNO on developing human fetal lungs remain vastly unknown. By using a well-characterized model of human fetal alveolar type II cells, we assessed the effects of iNO and hyperoxia, independently and concurrently, on NO-cGMP signaling pathway and differentiation. Exposure to iNO increased cGMP levels by 40-fold after 3 d and by 8-fold after 5 d despite constant expression of phosphodiesterase-5 (PDE5). The levels of cGMP declined significantly on exposure to iNO and hyperoxia at 3 and 5 d, although expression of soluble guanylyl cyclase (sGC) was sustained. Surfactant proteins B and C (SP-B, SP-C) and thyroid transcription factor (TTF)-1 mRNA levels increased in cells exposed to iNO in normoxia but not on exposure to iNO plus hyperoxia. Collectively, these data indicate an increase in type II cell markers when undifferentiated lung epithelial cells are exposed to iNO in room air. However, hyperoxia overrides these potentially beneficial effects of iNO despite sustained expression of sGC. A lveolar type II cells are critical for normal lung development as the source of pulmonary surfactant. The components of surfactant, which are necessary to construct a surface-active film at the alveolar surface thereby preventing alveolar collapse, are developmentally regulated. Specifically, surfactant proteins B and C (SP-B and SP-C) undergo complex regulation involving transcriptional and posttranscriptional events occurring through the second and third trimesters of human gestation (1-4). Premature infants are at high risk for developing RDS, in part, because of interruption of this process. Despite advances in obstetrical and neonatal management, including antenatal glucocorticoid therapy and postnatal surfactant administration, RDS remains a major cause of morbidity and mortality in preterm infants (5), often because it is a risk factor for the development of bronchopulmonary dysplasia (BPD). There remains great interest in identifying additional therapeutic agents that will enhance alveolar type II cell maturation and surfactant production to further reduce the risk of RDS and BPD.
A lveolar type II cells are critical for normal lung development as the source of pulmonary surfactant. The components of surfactant, which are necessary to construct a surface-active film at the alveolar surface thereby preventing alveolar collapse, are developmentally regulated. Specifically, surfactant proteins B and C (SP-B and SP-C) undergo complex regulation involving transcriptional and posttranscriptional events occurring through the second and third trimesters of human gestation (1) (2) (3) (4) . Premature infants are at high risk for developing RDS, in part, because of interruption of this process. Despite advances in obstetrical and neonatal management, including antenatal glucocorticoid therapy and postnatal surfactant administration, RDS remains a major cause of morbidity and mortality in preterm infants (5) , often because it is a risk factor for the development of bronchopulmonary dysplasia (BPD). There remains great interest in identifying additional therapeutic agents that will enhance alveolar type II cell maturation and surfactant production to further reduce the risk of RDS and BPD.
Nitric oxide (NO), a versatile endogenous mediator of vascular relaxation and signaling, has been effective in the treatment of term infants with pulmonary hypertension (6 -8) . The association of BPD with vascular pruning and pulmonary hypertension sparked interest in using NO to improve outcomes in preterm infants with hypoxic respiratory failure who are at risk of developing BPD. Until recently, clinical trials revealed mixed results (9 -12) . However, two large multicenter randomized clinical trials indicated beneficial effects of NO in preterm infants. Ballard et al. (13) reported significantly decreased rates of BPD and decreased need for supplemental oxygen in infants treated with inhaled NO (iNO). Kinsella et al. (14) also reported decreased BPD rates in infants with birth weight 1000 -1250 g, despite no overall difference in rates of BPD or death in the entire study population.
Studies performed in animal models revealed beneficial effects of iNO in alveolar epithelial physiology. The iNO preserves airway structure and function, enhances development of alveolae (15) , improves lung compliance and growth (16, 17) , decreases early lung inflammation and oxidant stress (18, 19) , and increases surfactant mRNA and protein levels (17,20 -24) . Endogenously produced by alveolar type II cells, NO participates in the transition from fluid-filled to airbreathing lungs at birth (25) . Despite these recognized beneficial effects of iNO in animal models, the molecular effects of exogenous NO have not been well characterized in human fetal lung.
Alveolar type II cells perform many critical functions that include production of pulmonary surfactant, transport of water and ions across the epithelium barrier, production of trophic factors and molecules that modulate inflammatory responses, and regeneration of type I cells on injury (1) (2) (3) . Alveolar type II cells differentiate from precursor epithelial cells during the second half of human gestation. Previously, we developed and extensively characterized an in vitro model of differentiation of type II cells by exposing isolated epithelial cells derived from human fetal lung explants to glucocorticoid and/or cAMP in serum-free media (26, 27) . Type II cell differentiation in this model is characterized by increased phosphatidylcholine synthesis, induction of SP synthesis, formation of lamellar bodies, and secretion of surface-active surfactant. This model has been valuable for exploring factors and genes, which regulate the differentiation of parenchymal epithelial cells to type II pneumocytes (26, 27) . In this study, this well-defined model system was used to test the hypothesis that NO will induce the differentiation of human fetal alveolar type II cell and counter the potential harmful effects of hyperoxia. Experiments also examined for the first time the expression of the enzymes that mediate the NO response, specifically the NOcGMP signaling pathway in human fetal type II cell cultures. Overall, the data provided new insights on the potential functions of NO in the developing lung and a mechanistic rationale for the use of iNO in the treatment of extremely preterm infants at risk for BPD.
MATERIALS AND METHODS
Cell culture. Enriched populations of epithelial cells from secondtrimester (16 -24 wk gestation) human fetal lung tissue were obtained from Advanced Bioscience Resources, Inc. (Alameda, CA) under Institutional Review Board-approved protocols and were processed as described previously (26) . After overnight culture, attached cells remained in serum-free Waymouth medium for 3 d. Next, the cells were cultured in 1 mL of serum-free Waymouth medium alone (control) or with 10 nM dexamethasone ϩ 0.1 mM 8-bromo-cAMP and 0.1 mM isobutylmethylxanthine (DCI) for 5 d to promote alveolar type II cell differentiation.
During the process of differentiation, cells were cultured at room air temperature in normoxia plus 5% CO 2 in a standard incubator (control) or in one of three test conditions ͓normoxia plus 20 ppm NO (Matheson Tri-Gas, Bridgeport, NJ), 95% oxygen alone, or 95% oxygen plus 20 ppm NO͔ in a Proox Model 110 chamber (BioSpherix, Redfield, NY) to maintain stable concentrations of oxygen, CO 2 , and NO. Because of the limited number of cells generated from each fetal lung tissue, only one experimental condition and a corresponding air-exposed control were analyzed at a time. This experimental design also accounts for biologic variance derived from the different human fetal lung tissues. The difference between the experimental treatment condition and the corresponding control group was used to determine the statistical significance of the data. Therefore, the data were presented as fold change compared with the corresponding air-exposed group.
cGMP enzyme immunoassay and NO metabolite analysis. cGMP and NO-derived metabolites were quantified by established methodologies described previously (28) . DNA analysis. DNA concentration was measured using fluorimetry with Hoechst dye (Molecular Probes, Eugene, OR). The standard curve of DNA fluorescence units was used to determine sample DNA concentration that was normalized to room air controls.
Real-time reverse transcriptase polymerase chain reaction. The two-step PCR protocol was performed as detailed elsewhere (29) .
Western blot analysis. Immunoblotting for SP-B, pepsinogen C (PGC), soluble guanylyl cyclase (sGC), phosphodiesterase 5 (PDE 5), and glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was performed using previously described procedures (3) .
Statistical analysis. Results are given as mean Ϯ SEM. To determine the statistical significance, we used aired t tests (performed using GraphPad Prism 4.00; GraphPad, San Diego, CA). All protein results were normalized to GAPDH, and RNA results were normalized to 18s rRNA.
RESULTS
Cellular responses to NO and hyperoxia. Cells cultured in hyperoxia exhibited altered viability compared with cells cultured in normoxia reflected by protein and DNA levels. Total protein recovered after 5 d of hyperoxia, with or without NO, was significantly decreased (hyperoxia 0.70 Ϯ 0.06, hyperoxia plus NO 0.50 Ϯ 0.04, values represent percent of normoxia control value; n ϭ 15 for normoxia and n ϭ 4 for hyperoxia and hyperoxia plus NO; p Ͻ 0.05). A modest but insignificant decrease in protein recovery from the cells exposed to normoxia plus NO (0.73 Ϯ 0.09, n Ϫ 3; p ϭ NS) was noted. Total cellular DNA recovery decreased moderately in cells exposed to normoxia plus NO (0.44 Ϯ 0.02), hyperoxia plus NO (0.73 Ϯ 0.4), and hyperoxia alone (0.64 Ϯ 0.17) when compared with normoxia controls (values represent percent of normoxia control value; n ϭ 11 for normoxia and n ϭ 3 for all other exposures; p ϭ NS). These results are consistent with the known toxicity of hyperoxia and the duality of NO as both a contributor to cell toxicity and a protector of cell viability (30) . The effects of NO in cell survival are a function of duration and level of NO exposure and the concomitant exposure to hyperoxia (30) . Consequently, all assays were performed using equal amounts of total protein, and densitometry-based assays were normalized to well-recognized housekeeping genes and proteins.
Activation of sGC and production of cGMP directly report on the delivery and utilization of iNO after exposure. The levels of cGMP were quantified in cells after 3 and 5 d of culture (Fig. 1A) . A significant elevation in cGMP levels occurred on d 3 in both the NO-exposed groups when compared with controls in normoxia and hyperoxia alone. How- ever, at d 3 the levels of cGMP were significantly lower in the iNO plus hyperoxia-exposed cells compared with cells exposed to iNO under normoxic conditions. Moreover, the cGMP levels in the NO-treated groups (both normoxia and hyperoxia) decreased significantly after 5 d of exposure, despite continuous exposure of the cells (Fig. 1A) .
The levels of stable products of NO metabolism were also significantly elevated in the media from cells cultured in DCI media and exposed to NO, with or without hyperoxia (Fig.  1B) . However, no difference was detected in the cell lysates (Fig. 1C) . Therefore, NO was delivered to the cells, and a corresponding activation of sCG accompanied the exposure.
Expression of sGC and PDE 5. The changes in cGMP levels prompted the investigation of the levels of sGC, the molecular target of NO, and the enzyme responsible for cGMP production. No significant differences in the expression of sGC were measured between exposure groups and the corresponding air-exposed controls on d 3 and 5 (Fig. 2) . The expression of PDE5, the major enzyme responsible for the metabolism of cGMP, was also assessed. Similarly, the levels of PDE5 did not vary significantly in the three treatment groups compared with corresponding air-exposed controls (Fig. 3) .
Thyroid transcription factor and SP mRNA with iNO and hyperoxic exposure. Real-time RT-PCR revealed increased expression of type II cell markers on d 5 in cells exposed to normoxia plus NO. Cells cultured with normoxia plus iNO had more than 2-fold increase in SP-B mRNA levels (Fig. 4A ) and more than 10-fold increase in SP-C mRNA levels (Fig.  4B ) compared with normoxia controls. Hyperoxia alone had no effect on SP-B or SP-C RNA. The effect of iNO on SP-B and SP-C mRNA did not extend to cells cultured in hyperoxia plus NO. The mRNA for thyroid transcription factor (TTF)-1, an essential transcription factor regulating SP synthesis, increased 5-fold in cells exposed to normoxia plus iNO (Fig.  4C ). This increase was not apparent in cells exposed to iNO plus hyperoxia.
Type II cell markers with iNO and hyperoxia. Mature SP-B protein was quantified by immunoblotting after exposure to various gas conditions (Fig. 5A) . As expected, a significant increase in mature SP-B was detected in cells cultured with the DCI media compared with cells cultured in control media (not shown). The SP-B protein levels were not significantly different in cells exposed to normoxia plus iNO compared with normoxia controls, despite the significant increase in SP-B mRNA. Mature SP-B levels declined by ϳ80% in cells exposed to hyperoxia compared with normoxia controls (Fig. 5B) . Exposure to iNO in the presence of hyperoxia did not prevent the decline in the levels of SP-B. The levels of PGC, an enzyme involved in SP-B posttranslational proteolytic processing (31), were not significantly altered in the different groups compared with normoxia controls (data not shown).
DISCUSSION
The iNO has been proven to be useful in the treatment of a variety of respiratory diseases of neonates and adults (6, 7, 13, 14) . Motivated by the encouraging results of the most recent clinical trials in neonates, we explored for the first time the responses of human fetal alveolar epithelial cells to iNO under normoxic and hyperoxic conditions. Because the production of surfactant is critically important for normal lung development, we hypothesized that NO/cGMP-induced differentiation of alveolar type II cells might contribute to the pulmonary benefits found in preterm infants treated with NO. By using a well-established in vitro model of fetal alveolar type II cell differentiation, the data revealed opposing regulatory functions of hyperoxia and iNO in the differentiation of human fetal type II pneumocytes.
By quantifying the levels of cGMP, the data indicated that exposure to iNO results in the activation of sGC. The activation of sGC and production of cGMP is one of the major pathways by which NO influences a variety of biologic functions including cellular differentiation (32) (33) (34) . The data also document for the first time that sGC is expressed by human fetal type II pneumocytes and, interestingly, the expression is maintained during hyperoxia. Previously, sGC and PDE5 were shown to increase during the perinatal period in rodents and were thought to be important in the transition to air breathing (35, 36) . However, the NO-stimulated activation of sGC and resultant production of cGMP significantly declined in the presence of hyperoxia. The diminished response to iNO in the presence of hyperoxia is not explained by a decline in the levels of sGC (Fig. 2) . The decrease in cGMP levels on d 3 of exposure to NO plus hyperoxia is also not derived from an increase in PDE5 protein, the main lung PDE that removes cGMP, the expression of which is actually decreased (Fig. 3) . The decline in cGMP levels may be due to inactivation of sGC or the reaction of NO with superoxide or other radical intermediates formed during hyperoxic exposures. It has been relatively well documented that hyperoxia increases the production of superoxide and other radicals and that exposure to hyperoxia and iNO alters the reactive nitrogen species formed in rodent lungs (37, 38) . Evidence for the formation of reactive nitrogen species derived from iNO are also present in the plasma of premature infants exposed to hyperoxia with or without iNO (37, 38) . Consistent with these findings are the documentation that hyperoxia decreased intracellular cGMP levels in ovine fetal pulmonary artery smooth muscle cells (39) . Compared with d 3, a significant decline in the levels of cGMP was noted on d 5 despite continuous exposure to iNO. The unexpected decline in cGMP levels after 5 d of iNO exposure may be explained by decreased responsiveness of sGC after prolonged iNO exposure despite stable protein levels similarly to the suggested tolerance induced by the use of systemic vasodilators (34) . Alternatively, it may indicate a rapid non-PDE5-regulated consumption of cGMP for signaling or other regulatory functions.
Significant increases in SP-B, SP-C, and TTF-1 mRNA were measured in cells treated with normoxia plus NO. This suggests that either more cells are differentiating to a type II phenotype or that increased levels of these products are being made by existing type II cells. Interestingly, these changes were not observed in conditions of hyperoxia plus NO, suggesting that high levels of oxygen may oppose the beneficial effects of NO. The levels of mature SP-B increased in cells treated with hormones but not on exposure to iNO despite increased levels of SP-B mRNA.
This study offers a number of new insights in the human fetal lung responses to hyperoxia and NO. As expected, exposure to iNO increased the levels of cGMP by activating sGC. Exposure of premature human fetal epithelial cells to normoxia plus NO leads to increased markers for type II pneumocytes, but these beneficial effects are not observed when NO is administered concomitantly with hyperoxia. Although rodent and other animal models of iNO, such as full-term lamb and premature baboon, demonstrated attenuation of certain aspects of hyperoxic lung injury, the data presented herein indicate that potential beneficial effects of NO in the maturation and differentiation of alveolar type II cells are mitigated by hyperoxia. Although this study did not explore the dose dependency of the interaction between hyperoxia and NO, the data support that efforts to lower exposure to hyperoxia in the clinical setting may help offset the detrimental effects of hyperoxia and promote the beneficial biologic consequences of iNO. 
